Cargando…

Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Guijarro, Luis G., Cano-Martínez, David, Toledo-Lobo, M. Val, Ruiz-Llorente, Lidia, Chaparro, María, Guerra, Iván, Iborra, Marisa, Cabriada, José Luis, Bujanda, Luis, Taxonera, Carlos, García-Sánchez, Valle, Marín-Jiménez, Ignacio, Barreiro-de Acosta, Manuel, Vera, Isabel, Martín-Arranz, María Dolores, Mesonero, Francisco, Sempere, Laura, Gomollón, Fernando, Hinojosa, Joaquín, Zoullas, Sofía, Monserrat, Jorge, Menor-Salvan, Cesar, Alvarez-Mon, Melchor, Gisbert, Javier P., Ortega, Miguel A., Hernández-Breijo, Borja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/
https://www.ncbi.nlm.nih.gov/pubmed/35327530
http://dx.doi.org/10.3390/biomedicines10030727
Descripción
Sumario:Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity.